8 research outputs found
Drug-eluting Bead Chemoembolization for the Treatment of Nonresectable Hepatic Carcinoma in Dogs: A Prospective Clinical Trial
Abstract Background Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. Hypothesis/Objective Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drugâeluting bead transarterial chemoembolization (DEBâTACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and shortâterm CT assessment would demonstrate stable disease or partial response. Animals Clientâowned dogs (n = 16) with nonresectable HC. Methods Prospective, singleâarm clinical trial. Drugâeluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12âweeks after initial treatment. Results Drugâeluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74âdays (range, 39â125) after initial treatment. Median tumor volume (mL) after DEBâTACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatmentâinduced death after 2/27 (7%) treatments. Median survival time after treatment was 337âdays (range, 22â1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126âdays; range, 46â337) than those dogs without prior history of weight loss (582âdays; range, 22â1061). Conclusions Drugâeluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample